Drug intelligence / Profile preview

Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang

Development stage
Unknown
Lead developer
Chang Gung Memorial Hospital
Modality
Small Molecules
Administration
Oral
01

Overview

This is a mixed Traditional Chinese Medicine (TCM) herbal formula consisting of three distinct classical formulas: Shin-yi-san (also known as Xin-yi-san), Xiao-qing-long-tang, and Xiang-sha-liu-jun-zi-tang. Developed and studied by Chang Gung Memorial Hospital in Taiwan, this combination is specifically investigated for the treatment of perennial allergic rhinitis. The formula exerts its therapeutic effects through complex immunomodulatory mechanisms, including the modulation of dendritic cells, CD4+ T lymphocytes, neutrophils, and regulatory B cells. It has been shown to suppress the expression of activation markers like HLA-DR, CD40, CD54, and CD86 on dendritic cells, while simultaneously enhancing the production of the anti-inflammatory cytokine IL-10 and reducing pro-inflammatory cytokines such as TNF-α, IL-4, IL-5, and IL-12. Additionally, research focuses on its impact on the gut microbiota as a potential pathway for immune regulation in allergic patients.

Other names
Xin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tangTCM for Perennial Allergic Rhinitis and Gut Microbiota
02

Targets

IL10 (Interleukin-10)IL-4 (Interleukin 4)ICAM1 (Intercellular Adhesion Molecule 1)CD86 (T-lymphocyte activation antigen CD86)IL-5 (Interleukin 5)CD40 (Cluster of differentiation 40 receptor)TNFA (Tumor necrosis factor alpha (soluble))HLA-DR (Human leukocyte antigen DR)

Beyond the preview

Go deeper on Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call